The latest warning letters from the US Food and Drug Administration show the agency still is finding manufacturing processes susceptible to diethylene glycol and ethylene glycol substitution and getting no response from some OTC firms to requests for records.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?